New
HealthMore in Health→
Triptolide Study Points to a Way Around Cancer Drug Resistance
Key Takeaways
- Triptolide blocked DCTPP1, an enzyme cancer cells can use to degrade DNMT inhibitors.
- Combining triptolide-related compounds with decitabine improved gene reactivation and cancer-cell killing in laboratory models.
- The finding is preclinical and does not demonstrate a safe or effective treatment in people.
DE
DT Editorial Team··via medicalxpress.com